Cellectis S.A.
CLLS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001627281
No open-market purchases or sales by Cellectis S.A. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $28.4M in total; no superinvestor holds it.
Holders of 5% or more of CLLS
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Cellectis S.A., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| AstraZeneca PLC | 13D/A | 44.00%44.0M shares | – | Jan 24, 20251 filing | Jan 24, 2025 | SEC |
| Bpifrance Participations SA | 13D/A | 11.10%10.6M shares | −2.00 ppfrom 13.10% | Jan 30, 20252 filings | Dec 12, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
3 Schedule 13D and 13G filings on Cellectis S.A., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Dec 12, 20254:05 PM ET | Bpifrance Participations SAand 4 others | 13D/A | 11.10%10.6M shares | −2.00 ppfrom 13.10% | Dec 3, 2025 | SEC |
| Jan 30, 20259:36 PM ET | Bpifrance Participations SAand 4 others | 13D/A | 13.10%10.3M shares | – | Jan 30, 2025 | SEC |
| Jan 24, 20259:52 AM ET | AstraZeneca PLCand 1 other | 13D/A | 44.00%44.0M shares | – | Jan 23, 2025 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Cellectis S.A. shares.
No Form 144 notices for Cellectis S.A. are on file.